Monitor for a prospectus supplement or takedown announcement under the effective shelf. The ability to issue shares introduces overhang, but no immediate dilution is expected. A capital raise in the near term would likely be dilutive for existing shareholders.
QTTB drugs
QTTB drug pipeline →How the stock moved after the report
⚠ Clustered NEUTRAL VIEWSTOCK BELOW ENTRY AT T+60- T+0 · Jul 14 $18.46entry
- T+1 · 4mo ago −14.95%α −15.35% · $15.70
- T+5 · 4mo ago −18.53%α −17.23% · $15.04
- T+20 · 3mo ago −16.52%α −19.01% · $15.41
- T+60 · 6w ago −56.72%α −60.09% · $7.99
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
Q32 Bio's S-3 shelf registration (File No. 333-297027) became effective on July 13, 2026, allowing the company to sell equity or debt securities at any time. As a pre-revenue biotech with significant operating losses, this creates potential dilution overhang, though no immediate offering has been announced.
Key Facts
- S-3 shelf registration became effective on July 13, 2026.
- Company can now issue an unlimited amount of securities (senior/subordinated debt, equity, etc.).
- Q32 Bio is a pre-revenue biotech with no product revenue and substantial operating losses.
Financial Impact
No specific offering amount disclosed; potential future capital raise dependent on company's funding needs.
Risk Factors
- Dilution risk if the company conducts an offering under the shelf.
- Requires additional capital to fund operations, increasing likelihood of future offerings.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 3 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| EFFECT Filing (Primary) | 9999999995-26-002273 |
| Document: 9999999995-26-002273-index.html | 9999999995-26-002273 |
| Document: 9999999995-26-002273.txt | 9999999995-26-002273 |
Track record
23 reports on QTTB
3 of 9 bullish or bearish reports moved the stock their way by T+20. Best: +48.47% at T+60 after the Jul 14, 2026 report. 6 of 9 went positive at some point.
Filters
- Nov 16, 2026today SC 13G/A Neutral 3/10 Entry $8.29 Now $8.29 −0.00% settles Dec 16
- Nov 16, 2026today SC 13G Neutral 3/10 Entry $8.47 Now $8.29 −2.13% settles Dec 15
- Nov 16, 2026today SC 13G/A Neutral 2/10 Entry $8.71 Now $8.29 −4.82% settles Dec 15
- Nov 6, 202610d ago SC 13G/A Neutral 3/10 Entry $9.34 Now $8.29 −11.24% settles Dec 8
- Nov 6, 202610d ago SC 13G/A Neutral 2/10 Entry $9.34 Now $8.29 −11.24% settles Dec 8
- Nov 4, 202612d ago 8-K Neutral 4/10 Entry $8.97 Now $8.29 −7.58% settles Dec 3
- Oct 28, 202619d ago SC 13G Neutral 4/10 Entry $9.06 Now $8.29 −8.50% settles Nov 25
- Oct 9, 20265w ago SC 13G Neutral 4/10 Entry $8.74 to $9.36 Now $8.29 −5.15% ▲ +7.09% +10.36% vs SPY
- Sep 30, 20266w ago 8-K Bullish 6/10 Entry $8.27 to $8.71 Now $8.29 +0.24% ▲ +5.32% +4.05% vs SPY
- Sep 14, 20269w ago 8-K Neutral 3/10 Entry $10.91 to $8.74 Now $8.29 −24.01% ▼ −19.89% −22.15% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers